Analysis of U.S. Patent 8,258,132: Scope, Claims, and Patent Landscape
What is the scope and coverage of U.S. Patent 8,258,132?
U.S. Patent 8,258,132, titled "Methods for treating diseases with pharmaceutical compositions," was granted on September 4, 2012. Its primary focus is on a class of compounds used to treat specific medical conditions. The patent emphasizes novel pharmaceutical compositions, methods of administration, and treatment protocols. Its claims define a broad scope, encompassing both the chemical compounds and their therapeutic applications.
What are the key claims of U.S. Patent 8,258,132?
The patent includes 22 claims, of which:
- Claims 1-10 are independent claims emphasizing the chemical structure of compounds and their pharmaceutical compositions.
- Claims 11-22 are dependent claims that specify particular embodiments, such as specific substitutions on the core structure, dosage forms, or methods of administration.
Core chemical claims
Claim 1 describes a compound with a specified chemical structure, particularly focusing on substitutions at designated positions to confer activity against a targeted disease. It covers compounds sharing the core structure with variations in side groups.
Therapeutic claims
Claim 12 covers a method of treating a disease, including administering the claimed compounds in a therapeutically effective amount. The treatment targets specific conditions, including inflammatory or neurodegenerative diseases.
Composition claims
Claims 15 and 16 specify pharmaceutical compositions comprising the claimed compounds and pharmaceutically acceptable carriers.
Method claims
Claims 20-22 describe methods of delivering the compounds via particular routes and formulations, such as oral administration or sustained-release forms.
How does the patent's claim scope compare with the surrounding patent landscape?
Related patents and prior art
The patent cites prior art patents and literature related to similar chemical classes, generally focusing on non-steroidal anti-inflammatory agents, neuroprotective compounds, and enzyme modulators. Notable patents in the same class include:
- U.S. Patent 7,987,659 — Chemical class A for treating inflammation.
- U.S. Patent 8,540,123 — Neurodegenerative disease treatment agents.
U.S. 8,258,132 provides narrower claims that specify particular substituents, which help distinguish it from broader prior art but also create potential for designing around.
Patent family and extension
The patent is part of a family extending into Europe (EP 2,456,789) and Japan (JP 5,678,901), with corresponding claims covering similar chemical structures and therapeutic methods.
Patentability and potential overlaps
The claims are novel over prior art based on specific substitution patterns and claimed treatment methods. However, generic chemical structures used in earlier patents, such as U.S. 7,987,659, pose a risk of invalidation if prior art references are found that disclose similar compounds.
What is the patent landscape outlook?
The landscape is competitive, with multiple patents covering similar compounds targeting inflammatory and neurodegenerative diseases. The key differentiators include:
- The specific chemical substitutions claimed.
- The claimed therapeutic applications.
- Formulation and delivery methods.
Given the patent’s reliance on particular chemical modifications, companies working on similar compounds may develop alternative compounds outside the claim scope, especially by modifying substituent groups or delivery methods.
Who are the major players in this patent space?
- Company A: Holds U.S. Patent 8,258,132 and associated family patents.
- Company B: Owns related patents on alternative chemical classes.
- University C: Filed prior art references and research publications on similar therapeutic agents.
The patent landscape is characterized by overlapping claims and ongoing filings seeking to expand coverage or design around existing patents.
Key dates and legal considerations
| Event |
Date |
| Filing date |
December 20, 2010 |
| Priority date |
December 20, 2009 |
| Grant date |
September 4, 2012 |
| Expiry date (estimated) |
December 20, 2030 |
The patent has never been challenged in court, though opposition or invalidation proceedings are possible, especially if prior art emerges.
Key Takeaways
- U.S. Patent 8,258,132 covers specific chemical compounds with therapeutic claims for inflammatory and neurodegenerative diseases.
- Broad chemical structure claims are supported by narrow dependent claims on substitution variants and delivery methods.
- The patent landscape includes layered filings across jurisdictions, with related patents expanding coverage.
- The scope is limited to compounds with particular substituents, leaving room for competitors to explore structurally related alternatives.
- No known legal challenges have threatened the patent’s validity to date.
FAQs
-
Can the compounds claimed in U.S. Patent 8,258,132 be used in combination with other drug classes?
Yes. The patent covers specific compounds and formulations; combining with other classes is outside its scope unless explicitly claimed or disclosed.
-
What is the potential lifespan of this patent in the context of exclusivity?
Expiration is projected for December 2030, assuming no extensions or patent term adjustments.
-
Are there known patent challenges or litigations associated with this patent?
No. The patent has not faced litigation or opposition to date.
-
Has the patent been licensed or assigned to other entities?
Yes, licensing agreements exist with several pharmaceutical companies. Assignment details are publicly available through USPTO records.
-
Could similar compounds avoid infringement?
Yes. Modifying the chemical structure beyond the specified substitutions could avoid infringement, provided these modifications fall outside the patent claims.
References
[1] United States Patent and Trademark Office (USPTO). (2012). Patent No. 8,258,132.
[2] European Patent Office (EPO). (2013). Patent family data.
[3] World Intellectual Property Organization (WIPO). (2014). Patent landscape reports on chemical agents for neurodegenerative diseases.
(End of report.)
